Pharmacokinetic immunoassay methods in the presence of soluble target

Journal of Immunological Methods

Volumn 361, Issue 1-2, 2010, Pages 75-81

  Verch, Thorsten ^a   Chilewski, Shannon ^a,b   Bouaraphan, Silikhone ^a   Yarovoi, Helen ^a   Yin, Kuo Chang ^a   Chen, Dave ^a,c   Washabaugh, Michael W ^a,d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c ANP Technologies Inc   (United States)

^d MEDIMMUNE   (United States)

Author keywords

ELISA; Immunoassay; Pharmacokinetic; Soluble target; Therapeutic antibody

Indexed keywords

ANTIBODY; DICKKOPF 1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; ANTIIDIOTYPIC ANTIBODY; DKK1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE; SIGNAL PEPTIDE;

ANTIBODY AFFINITY; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOASSAY; PRIORITY JOURNAL; HUMAN; IMMUNOLOGY; PROCEDURES;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOASSAY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; RECEPTOR, ERBB-2; SERINE ENDOPEPTIDASES; TUMOR NECROSIS FACTOR-ALPHA; PROPROTEIN CONVERTASES;

EID: 77956878756     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2010.07.014     Document Type: Article

References (25)

1. Careskey H.E., Davis R.A., Alborn W.E., Troutt J.S., Cao G., Konrad R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type. J. Lipid Res. 2008, 9:394.
2. Carney W.P., Neumann R., Lipton A., Leitzel K., Ali S., Price C.P. Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin. Chem. 2003, 1579.
3. Doucet J., Avrameas A. A novel method for quantitative measurement of a therapeutic monoclonal antibody in the presence of its target protein using enzymatic digestion. J. Pharm. Biomed. Anal. 2010, 565.
4. Fisher T.S., Lo S.P., Pandit S., Mattu M., Santoro J.C., Wisniewski D., Cummings R.T., Calzetta A., Cubbon R.M., Fischer P.A., Tarachandani A., De Francesco R., Wright S.D., Sparrow C.P., Carfi A., Sitlani A. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J. Biol. Chem. 2007, 20502.
5. Hedrick J.A. Targeting PCSK9 for the treatment of hypercholesterolemia. Curr. Opin. Investig. Drugs 2009, 938.
6. Kostler W.J., Schwab B., Singer C.F., Neumann R., Rucklinger E., Brodowicz T., Tomek S., Niedermayr M., Hejna M., Steger G.G., Krainer M., Wiltschke C., Zielinski C.C. Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin. Cancer Res. 2004, 1618.
7. Lopez D. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia. Drug News Perspect. 2008, 323.
8. Lopez D. PCSK9: an enigmatic protease. Biochim. Biophys. Acta 2008, 184.
9. Luftner D., Luke C., Possinger K. Serum HER-2/neu in the management of breast cancer patients. Clin. Biochem. 2003, 233.
10. Maple L., Lathrop R., Bozich S., Harman W., Tacey R., Kelley M., Danilkovitch-Miagkova A. Development and validation of ELISA for herceptin detection in human serum. J. Immunol. Methods 2004, 169.
11. Patton A., Mullenix M.C., Swanson S.J., Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J. Immunol. Methods 2005, 189.
12. Pinzone J.J., Hall B.M., Thudi N.K., Vonau M., Qiang Y.W., Rosol T.J., Shaughnessy J.D. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 2009, 517.
13. Qian J., Xie J., Hong S., Yang J., Zhang L., Han X., Wang M., Zhan F., Shaughnessy J.D., Epstein J., Kwak L.W., Yi Q. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 2007, 1587.
14. Roch A.M., Delcros J.G., Ripoll J.P., Thomas V., Richard J., Quash G. A novel covalent enzyme-linked immunoassay (CELIA) for simultaneously measuring free and immune complex bound antibodies of defined specificity. I. Application to naturally occurring antipolyamine antibodies in human sera. J. Immunol. Methods 1990, 1.
15. Saghatchian M., Guepratte S., Hacene K., Neumann R., Floiras J.L., Pichon M.F. Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int. J. Biol. Markers Int. 2004, 14.
16. Saito K., Kobayashi D., Sasaki M., Araake H., Kida T., Yagihashi A., Yajima T., Kameshima H., Watanabe N. Detection of human serum tumor necrosis factor-alpha in healthy donors, using a highly sensitive immuno-PCR assay. Clin. Chem. 1999, 665.
17. Salvadori B., Pinzani P., Distante V., Casella D., Bianchi S., Paglierani M., Vezzosi V., Neumann R., Cataliotti L., Pazzagli M., Orlando C. Comparison of pre- and postsurgical concentrations of blood HER-2 mRNA and HER-2 extracellular domain reflects HER-2 status in early breast cancer. Clin. Chem. 2005, 254.
18. Schondorf T., Hoopmann M., Warm M., Neumann R., Thomas A., Gohring U.J., Eisberg C., Mallmann P. Serologic concentrations of HER-2/neu in breast cancer patients with visceral metastases receiving trastuzumab therapy predict the clinical course. Clin. Chem. 2002, 1360.
19. Sheng S.L., Huang G., Yu B., Qin W.X. Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin. Chem. 2009, 1656.
20. Ternant D., Mulleman D., Degenne D., Willot S., Guillaumin J.M., Watier H., Goupille P., Paintaud G. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther. Drug Monit. 2006, 169.
21. Tetta C., Camussi G., Modena V., Di Vittorio C., Baglioni C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann. Rheum. Dis. 1990, 665.
22. Thomas V., El Alaoui S., Roch A.M., Quash G. A novel covalent enzyme-linked immunoassay (CELIA) for simultaneously measuring free and immune complex bound antibodies with a defined specificity. II. Application to immune complexes containing viral antigens in human sera. J. Immunol. Methods 1990, 13.
23. Watanabe N., Akikusa B., Park S.Y., Ohno H., Fossati L., Vecchietti G., Gessner J.E., Schmidt R.E., Verbeek J.S., Ryffel B., Iwamoto I., Izui S., Saito T. Mast cells induce autoantibody-mediated vasculitis syndrome through tumor necrosis factor production upon triggering Fcgamma receptors. Blood 1999, 3855.
24. Weinberg J.M., Buchholz R. TNF-alpha Inhibitors 2006, Springer, Birkhäuser Basel.
25. Zwolinska D., Medynska A., Szprynger K., Szczepanska M. Serum concentration of IL-2, IL-6, TNF-alpha and their soluble receptors in children on maintenance hemodialysis. Nephron 2000, 441.